Literature DB >> 25158892

Hydroxyethyl starch: a review of pharmacokinetics, pharmacodynamics, current products, and potential clinical risks, benefits, and use.

Polly A Glover1, Elke Rudloff, Rebecca Kirby.   

Abstract

OBJECTIVE: To review and summarize the pharmacokinetics and pharmacodynamics of hydroxyethyl starch (HES), as well as reported risks and benefits of HES infusion, and to provide administration and monitoring recommendations for HES use in dogs and cats. DATA SOURCES: Veterinary and human peer-reviewed medical literature, including scientific reviews, clinical and laboratory research articles, and authors' clinical experience.
SUMMARY: HES solutions are the most frequently used synthetic colloid plasma volume expanders in human and veterinary medicine. The majority of research in human medicine has focused on the adverse effects of HES infusion, with emphasis on acute kidney injury and coagulation derangements. The studies often differ in or fail to report factors, such as the type, amount, interval, and concentration of HES administered; the patient population studied; or concurrent fluids administered. Currently, there is no definitive clinical evidence that the reported adverse effects of HES use in human medicine occur in veterinary species. There is little information available on HES administration techniques or simultaneous administration of additional fluids in human and veterinary medicine. The rationale for HES use in small animals has been largely extrapolated from human medical studies and guidelines. A controlled approach to intravenous fluid resuscitation using crystalloid and HES volumes titrated to reach desired resuscitation end point parameters is outlined for small animal practitioners.
CONCLUSION: The extrapolation of data from human studies directly to small animals should be done with the knowledge that there may be species variations and different pharmacokinetics with different HES solutions. Veterinary reports indicate that bolus and continuous rate infusions of 6% hetastarch solutions at moderate doses are well tolerated in feline and canine subjects. Further research in domesticated species is necessary to better define and expand the knowledge regarding use of HES solutions in small animal medicine. © Veterinary Emergency and Critical Care Society 2014.

Entities:  

Keywords:  canine and feline; hetastarch; plasma substitutes

Mesh:

Substances:

Year:  2014        PMID: 25158892     DOI: 10.1111/vec.12208

Source DB:  PubMed          Journal:  J Vet Emerg Crit Care (San Antonio)        ISSN: 1476-4431


  19 in total

Review 1.  Hydroxyethyl starch and its derivatives as nanocarriers for delivery of diagnostic and therapeutic agents towards cancers.

Authors:  Ronghua Tan; Ying Wan; Xiangliang Yang
Journal:  Biomater Transl       Date:  2020-12-28

2.  Outcome of horses with enterocolitis receiving oncotic fluid support with either plasma or hetastarch.

Authors:  Jamie J Kopper; Clark J Kogan; Vanessa L Cook; Harold C Schott
Journal:  Can Vet J       Date:  2019-11       Impact factor: 1.008

3.  Current Trends in Volume Replacement Therapy and the Use of Synthetic Colloids in Small Animals-An Internet-Based Survey (2016).

Authors:  Ivayla D Yozova; Judith Howard; Nadja E Sigrist; Katja-Nicole Adamik
Journal:  Front Vet Sci       Date:  2017-09-04

4.  Changes in Serum Creatinine Concentration and Acute Kidney Injury (AKI) Grade in Dogs Treated with Hydroxyethyl Starch 130/0.4 From 2013 to 2015.

Authors:  N E Sigrist; N Kälin; A Dreyfus
Journal:  J Vet Intern Med       Date:  2017-01-21       Impact factor: 3.333

5.  Doxorubicin-Bound Hydroxyethyl Starch Conjugate Nanoparticles with pH/Redox Responsive Linkage for Enhancing Antitumor Therapy.

Authors:  Ronghua Tan; Danlei Tian; Jiaoyan Liu; Congcong Wang; Ying Wan
Journal:  Int J Nanomedicine       Date:  2021-07-05

6.  In vitro effects of 6 % hydroxyethyl starch 130/0.42 solution on feline whole blood coagulation measured by rotational thromboelastometry.

Authors:  Nathalie A Albrecht; Judith Howard; Alan Kovacevic; Katja N Adamik
Journal:  BMC Vet Res       Date:  2016-07-26       Impact factor: 2.741

7.  Thromboelastometric assessment of hemostasis following hydroxyethyl starch (130/0.4) administration as a constant rate infusion in hypoalbuminemic dogs.

Authors:  Angelica Botto; Barbara Bruno; Cristiana Maurella; Fulvio Riondato; Alberto Tarducci; Giulio Mengozzi; Antonio Borrelli
Journal:  BMC Vet Res       Date:  2018-01-31       Impact factor: 2.741

8.  Effects of Hydroxyethyl Starch 130/0.4 on Serum Creatinine Concentration and Development of Acute Kidney Injury in Nonazotemic Cats.

Authors:  N E Sigrist; N Kälin; A Dreyfus
Journal:  J Vet Intern Med       Date:  2017-09-01       Impact factor: 3.333

9.  Effects of 6% Tetrastarch and Lactated Ringer's Solution on Extravascular Lung Water and Markers of Acute Renal Injury in Hemorrhaged, Isoflurane-Anesthetized Healthy Dogs.

Authors:  M S Diniz; F J Teixeira-Neto; N Celeita-Rodríguez; C H Girotto; M W Fonseca; A C Oliveira-Garcia; B López-Castañeda
Journal:  J Vet Intern Med       Date:  2018-01-28       Impact factor: 3.333

10.  Effects of 6% tetrastarch or lactated Ringer's solution on blood coagulation in hemorrhaged dogs.

Authors:  Miriely S Diniz; Francisco J Teixeira-Neto; Daniele S Gonçalves; Nathalia Celeita-Rodríguez; Carolina H Girotto; Mariana W Fonseca; Regina K Takahira
Journal:  J Vet Intern Med       Date:  2018-10-25       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.